<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2742">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 07, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04328129</url>
  </required_header>
  <id_info>
    <org_study_id>2020-009</org_study_id>
    <nct_id>NCT04328129</nct_id>
  </id_info>
  <brief_title>Household Transmission Investigation Study for COVID-19 in Tropical Regions</brief_title>
  <acronym>EPI-COVID-19</acronym>
  <official_title>Household Transmission Investigation Study for Coronavirus Disease 2019 (COVID-19) in Tropical Regions</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut Pasteur</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Institut Pasteur de la Guyane</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Centre Hospitalier Andrée Rosemon de Cayenne</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Institut Pasteur de la Guadeloupe</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Centre Hospitalier de la Guadeloupe</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Institut Pasteur de Nouvelle-Calédonie</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Centre Hospitalier Territorial de Nouvelle Calédonie</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Institut Pasteur</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a interventional study that present minimal risks and constraints to evaluate
      the presence of novel coronavirus (SARS-CoV-2) or antibodies among individuals living in
      households where there is a confirmed coronavirus case in order to provide useful information
      on the proportion of symptomatic forms and the extent of the virus transmission in tropical
      regions such as French Guiana, Guadeloupe and New-Caledonia.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is a interventional study that present minimal risks and constraints to evaluate
      the presence of novel coronavirus (SARS-CoV-2) or antibodies among individuals living in
      households where there is a confirmed coronavirus case in order to provide useful information
      on the proportion of symptomatic forms and the extent of the virus transmission in tropical
      regions such as French Guiana, Guadeloupe and New-Caledonia.

      Subjects will be assessed (questionnaires and sampling) in their homes. Subjects will be
      asked to attend study visits at days 0, 7, 14, 21, 28, 60, 90, 180 and 360.

      The primary objective of the study is to evaluate the rate of intra-household secondary
      transmission of the virus.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 23, 2020</start_date>
  <completion_date type="Anticipated">March 23, 2022</completion_date>
  <primary_completion_date type="Anticipated">March 23, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Screening</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluation of the extent of the virus transmission within households</measure>
    <time_frame>2 years</time_frame>
    <description>The extent of the virus transmission within households will be assessed by evaluating the rate of intra-household secondary transmission of the virus</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Characterization of the secondary cases</measure>
    <time_frame>2 years</time_frame>
    <description>The characterization of the secondary cases will be assessed by evaluating the proportion of asymptomatic forms within the household</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Characterization of the secondary cases</measure>
    <time_frame>2 years</time_frame>
    <description>The characterization of the secondary cases will be assessed by characterizing the risk factors for coronavirus infection.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>In New-Caledonia, evaluation of the extent of the virus transmission within contact persons</measure>
    <time_frame>2 years</time_frame>
    <description>The extent of the virus transmission within contact persons will be assessed by evaluating the rate of extended-contact secondary transmission of the virus</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">1300</enrollment>
  <condition>Coronavirus Infections</condition>
  <condition>Severe Acute Respiratory Syndrome</condition>
  <condition>SARS-CoV Infection</condition>
  <arm_group>
    <arm_group_label>Primary case</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subject with laboratory-confirmed coronavirus SARS-CoV-2 infection by polymerase chain reaction (PCR)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Family contact</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subject who lived in the household of the primary case while the primary case was symptomatic</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Human biological samples</intervention_name>
    <description>Blood sample
Nasopharyngeal swab.</description>
    <arm_group_label>Family contact</arm_group_label>
    <arm_group_label>Primary case</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Primary case: laboratory-confirmed coronavirus SARS-CoV-2 infection by polymerase
             chain reaction (PCR),

        or Family contact in French Guiana and Guadeloupe: person who lived in the same household
        as the primary case of COVID-19 when the primary case was symptomatic. A household is
        defined as a group of people (2 or more) living in the same accommodation (excluding
        residential institutions such as boarding schools, dormitories, hostels, prisons, other
        communities hosting grouped people),

        or Close contact in New-Caledonia: any individual who was in contact with a primary case,
        in his/her family/living environment, work/school, friends/leisure or means of transport,
        when the primary case was symptomatic or presymptomatic,

          -  Affiliated or beneficiary of a social security system

          -  Informed consent prior to initiation of any study procedures from subject (or legally
             authorized representative)

          -  State of health compatible with a blood sample as defined in the protocol.

        Exclusion Criteria:

          -  Inability to consent

          -  Person under guardianship or curatorship

          -  Known pathology or a health problem contraindicated with the collect of blood sample.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Claude Flamand, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institut Pasteur de la Guyane, Head of Epidemiology Unit</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Claude Flamand, Phd</last_name>
    <phone>+33 5 94 29 26 15</phone>
    <email>cflamand@pasteur-cayenne.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Dominique Rousset, MD</last_name>
    <phone>+33 5 94 29 26 09</phone>
    <email>drousset@pasteur-cayenne.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Centre Hospitalier Andrée Rosemon</name>
      <address>
        <city>Cayenne</city>
        <country>French Guiana</country>
      </address>
    </facility>
    <status>Enrolling by invitation</status>
  </location>
  <location>
    <facility>
      <name>Institut Pasteur de la Guyane</name>
      <address>
        <city>Cayenne</city>
        <country>French Guiana</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Claude Flamand, PhD</last_name>
      <phone>+33 5 94 29 26 15</phone>
      <email>cflamand@pasteur-cayenne.fr</email>
    </contact>
    <contact_backup>
      <last_name>Dominique Rousset, MD</last_name>
      <phone>+33 5 94 29 26 09</phone>
      <email>drousset@pasteur-cayenne.fr</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Institut Pasteur de Guadeloupe</name>
      <address>
        <city>Les Abymes</city>
        <country>Guadeloupe</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Stéphanie Guyomard-Rabenrina, MD</last_name>
    </contact>
    <contact_backup>
      <email>sguyomard@pasteur-guadeloupe.fr</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Institut Pasteur de Nouvelle-Calédonie</name>
      <address>
        <city>Nouméa</city>
        <country>New Caledonia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Myrielle Dupont-Rouzeyrol, PhD</last_name>
    </contact>
    <contact_backup>
      <email>mdupont@pasteur.nc</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>French Guiana</country>
    <country>Guadeloupe</country>
    <country>New Caledonia</country>
  </location_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>March 23, 2020</study_first_submitted>
  <study_first_submitted_qc>March 27, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 31, 2020</study_first_posted>
  <last_update_submitted>September 21, 2020</last_update_submitted>
  <last_update_submitted_qc>September 21, 2020</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 23, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>SARS-CoV-2</keyword>
  <keyword>COVID-19</keyword>
  <keyword>Serology</keyword>
  <keyword>French Guiana</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Coronavirus Infections</mesh_term>
    <mesh_term>Severe Acute Respiratory Syndrome</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

